164 related articles for article (PubMed ID: 9578421)
41. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
[TBL] [Abstract][Full Text] [Related]
42. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
43. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
44. Coexpression of MAGE-A peptides and HLA class I molecules in hepatocellular carcinoma.
Roch N; Kutup A; Vashist Y; Yekebas E; Kalinin V; Izbicki JR
Anticancer Res; 2010 May; 30(5):1617-23. PubMed ID: 20592351
[TBL] [Abstract][Full Text] [Related]
45. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.
Sigalotti L; Fratta E; Coral S; Tanzarella S; Danielli R; Colizzi F; Fonsatti E; Traversari C; Altomonte M; Maio M
Cancer Res; 2004 Dec; 64(24):9167-71. PubMed ID: 15604288
[TBL] [Abstract][Full Text] [Related]
46. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
[TBL] [Abstract][Full Text] [Related]
47. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1.
Marchand M; Brasseur F; van der Bruggen P; Coulie P; Boon T
Dermatology; 1993; 186(4):278-80. PubMed ID: 8513199
[TBL] [Abstract][Full Text] [Related]
48. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
Salgaller ML; Weber JS; Koenig S; Yannelli JR; Rosenberg SA
Cancer Immunol Immunother; 1994 Aug; 39(2):105-16. PubMed ID: 7519125
[TBL] [Abstract][Full Text] [Related]
49. [Molecular biology of lung cancer series].
Hiret S; Senellart H; Bennouna J
Rev Mal Respir; 2010 Oct; 27(8):954-8. PubMed ID: 20965409
[TBL] [Abstract][Full Text] [Related]
50. Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen.
Reed DS; Romero P; Rimoldi D; Cerottini JC; Schaack J; Jongeneel CV
Int J Cancer; 1997 Sep; 72(6):1045-55. PubMed ID: 9378539
[TBL] [Abstract][Full Text] [Related]
51. Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis.
Overes IM; de Rijke B; van Horssen-Zoetbrood A; Fredrix H; de Graaf AO; Jansen JH; van Krieken JH; Raymakers RA; van der Voort R; de Witte TM; Dolstra H
Br J Haematol; 2008 Jun; 141(6):799-807. PubMed ID: 18410452
[TBL] [Abstract][Full Text] [Related]
52. A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules.
Luiten RM; Demotte N; Tine J; van der Bruggen P
Tissue Antigens; 2000 Jul; 56(1):77-81. PubMed ID: 10958359
[TBL] [Abstract][Full Text] [Related]
53. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen.
Hoon DS; Yuzuki D; Hayashida M; Morton DL
J Immunol; 1995 Jan; 154(2):730-7. PubMed ID: 7814879
[TBL] [Abstract][Full Text] [Related]
54. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.
Van den Eynde B; Peeters O; De Backer O; Gaugler B; Lucas S; Boon T
J Exp Med; 1995 Sep; 182(3):689-98. PubMed ID: 7544395
[TBL] [Abstract][Full Text] [Related]
55. [Establishment of B16-HLA-MAGE-3 melanoma cell line coexpressing HLA-A 0201/K(b) and MAGE-3 and its role in tumor vaccine evaluation].
Song SX; Yan CZ; Zheng L; You HY; Wang JX; Liu FY
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Jul; 24(7):679-82. PubMed ID: 18616910
[TBL] [Abstract][Full Text] [Related]
56. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
Traversari C; van der Bruggen P; Luescher IF; Lurquin C; Chomez P; Van Pel A; De Plaen E; Amar-Costesec A; Boon T
J Exp Med; 1992 Nov; 176(5):1453-7. PubMed ID: 1402688
[TBL] [Abstract][Full Text] [Related]
57. Expression of MAGE genes in osteosarcoma.
Sudo T; Kuramoto T; Komiya S; Inoue A; Itoh K
J Orthop Res; 1997 Jan; 15(1):128-32. PubMed ID: 9066537
[TBL] [Abstract][Full Text] [Related]
58. Assessment of messenger RNA of beta 1-->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma.
Kuo CT; Bostick PJ; Irie RF; Morton DL; Conrad AJ; Hoon DS
Clin Cancer Res; 1998 Feb; 4(2):411-8. PubMed ID: 9516930
[TBL] [Abstract][Full Text] [Related]
59. Heterogeneity of biologic responses of melanoma-specific CTL.
Fonteneau JF; Le Dréan E; Le Guiner S; Gervois N; Diez E; Jotereau F
J Immunol; 1997 Sep; 159(6):2831-9. PubMed ID: 9300706
[TBL] [Abstract][Full Text] [Related]
60. T cell recognition of melanoma antigens in association with HLA-A1 on allogeneic melanoma cells.
Chen Q; Smith M; Nguyen T; Maher DW; Hersey P
Cancer Immunol Immunother; 1994 Jun; 38(6):385-93. PubMed ID: 8205560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]